Compare · NVO vs ZSTK
NVO vs ZSTK
Side-by-side comparison of Novo Nordisk A/S (NVO) and ZeroStack Corp. (ZSTK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ZSTK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 1540.0x ZSTK ($139.9M).
- Over the past year, NVO is down 12.1% and ZSTK is down 69.2% - NVO leads by 57.1 points.
- ZSTK has been more active in the news (17 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for ZSTK).
- Company
- Novo Nordisk A/S
- ZeroStack Corp.
- Price
- $48.65+3.65%
- $6.46+30.21%
- Market cap
- $215.46B
- $139.9M
- 1M return
- -2.08%
- +341.30%
- 1Y return
- -12.07%
- -69.17%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 9
- 17
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest ZSTK
- SEC Form S-3 filed by ZeroStack Corp.
- SEC Form S-8 POS filed by ZeroStack Corp.
- SEC Form S-8 POS filed by ZeroStack Corp.
- SEC Form S-8 POS filed by ZeroStack Corp.
- SEC Form S-8 POS filed by ZeroStack Corp.
- SEC Form S-8 POS filed by ZeroStack Corp.
- SEC Form S-8 POS filed by ZeroStack Corp.
- SEC Form S-8 POS filed by ZeroStack Corp.
- Zerostack Corp. Reports Cryptocurrency Holdings with Aggregate Market Value of Approximately $1.06 Billion, Representing Approximately $18.19 Per Partially Diluted Share
- President Rong Rudy sold $7,570 worth of shares (1,000 units at $7.57), closing all direct ownership in the company (SEC Form 4)